This product provides a CRISPR/Cas9-edited polyclonal A-549 cell population with targeted disruption of the ARRDC1 gene, encoding the alpha-arrestin adaptor protein ARRDC1. The polyclonal knockout pool retains the genetic heterogeneity inherent to the A-549 lung adenocarcinoma epithelial line, making it suitable for pooled functional screening and bulk biochemical analyses where clonal homogeneity is not required. The ARRDC1 polyclonal knockout cells serve as a versatile loss-of-function model to investigate the roles of ARRDC1 in membrane protein trafficking and receptor downregulation pathways.
The host cell line, A-549, is a human lung adenocarcinoma epithelial cell line originally derived from the lung tissue of a 58-year-old male. It is a widely characterized model for lung adenocarcinoma, exhibiting key features such as EGFR expression and functional endocytic machinery, which are critical for studying receptor-mediated signaling and trafficking. A-549 cells are frequently employed in cancer cell biology to dissect mechanisms of proliferation, apoptosis, and drug resistance, providing a physiologically relevant background for ARRDC1 functional studies.
ARRDC1 is a member of the alpha-arrestin family that functions as an adaptor in ubiquitin-dependent lysosomal sorting and degradation of membrane proteins. It recognizes ubiquitylated cargo such as activated EGFR and certain GPCRs, and through its interactions with Nedd4 family ubiquitin ligases, it recruits the ESCRT machinery, including components TSG101 and VPS37. This process facilitates the sorting of receptors into intraluminal vesicles of multivesicular bodies, ultimately targeting them for lysosomal degradation. By promoting receptor downregulation, ARRDC1 attenuates downstream signaling cascades, including the EGFR??MAPK/ERK pathway. Additional interacting partners include clathrin and the AP-2 complex, linking ARRDC1 to endocytic vesicle formation. Phosphorylation signals and ubiquitination status upstream of ARRDC1 further regulate its activity, integrating signals to control receptor turnover.
In the A-549 lung adenocarcinoma context, disruption of ARRDC1 provides a powerful approach to dissect the contribution of ubiquitin-dependent lysosomal sorting to EGFR signaling homeostasis and tumor cell biology. Aberrant EGFR signaling is a hallmark of many lung adenocarcinomas, and defects in receptor downregulation can lead to sustained proliferative signals and therapeutic resistance. By eliminating ARRDC1, researchers can assess how impaired lysosomal degradation alters EGFR surface levels, signaling activity, and therapeutic responses. Additionally, ARRDC1??s role in sorting other oncogenic receptors broadens the model??s utility for investigating general protein trafficking defects in cancer.
The ARRDC1 polyclonal knockout A-549 cells are ideally suited for studies of lysosomal sorting defects and receptor downregulation in lung adenocarcinoma. Researchers can employ time-course Western blotting to monitor EGFR degradation kinetics, flow cytometry to quantify surface receptor levels, and co-immunoprecipitation to assess ARRDC1 interactions with Nedd4 and ESCRT components. Immunofluorescence microscopy enables visualization of cargo missorting, while RT-qPCR probes transcriptional changes. These assays facilitate investigation of ubiquitin-dependent trafficking and drug resistance mechanisms. For further details, please contact Ascent Research.
